MedTrace Logo

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

NCT06805994 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2025-09-04

No results posted yet for this study

Summary

This protocol aims to evaluate how NMT affects pediatric nasal microbiome diversity following intranasal mupirocin treatment

Conditions

  • Staphylococcal Aureus Infection
  • Microbial Colonization
  • Pediatric Infection
  • S. Aureus Colonization
  • Microbial Transplant

Interventions

BIOLOGICAL

Nasal Microbiota Transplant (NMT)

nasal microbiota transplant

BIOLOGICAL

Placebo

Placebo sterile swab

Sponsors & Collaborators

Principal Investigators

  • Aaron M Milstone, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
0 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-27
Primary Completion
2027-09-01
Completion
2028-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06805994 on ClinicalTrials.gov